Differences in the Clinical Characteristics and 1-Year Mortality Rates of Patients with Dermatomyositis with anti-Jo-1 and anti-MDA5 Antibodies
Objective. Patients with anti-Jo-1 antibodies (Abs) and anti–melanoma differentiation-associated protein 5 (MDA5) Abs are at a higher risk of interstitial lung disease (ILD) and have a mortality rate higher than that of patients with anti-Jo-1 Abs. This study investigated differences in the clinical...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2023/2988422 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849470191905275904 |
|---|---|
| author | Chao-Han Liu Chew-Teng Kor Ming-Hui Hung Kai-Hung Hsiao Yen-Huang Cheng Ya-Chih Tien |
| author_facet | Chao-Han Liu Chew-Teng Kor Ming-Hui Hung Kai-Hung Hsiao Yen-Huang Cheng Ya-Chih Tien |
| author_sort | Chao-Han Liu |
| collection | DOAJ |
| description | Objective. Patients with anti-Jo-1 antibodies (Abs) and anti–melanoma differentiation-associated protein 5 (MDA5) Abs are at a higher risk of interstitial lung disease (ILD) and have a mortality rate higher than that of patients with anti-Jo-1 Abs. This study investigated differences in the clinical characteristics and prognosis of patients with anti-Jo-1 Abs and anti-MDA5 Abs with dermatomyositis (DM). Methods. We retrospectively reviewed the medical records of 38 patients with DM from January 2000 to December 2021. The patients were divided into anti-Jo-1 Abs and anti-MDA5 Abs groups. The basic demographic data, clinical manifestations, and 1-year mortality rates of the groups were compared. Results. Among the 38 patients, 30 were anti-Jo-1-Abs positive and 8 patients were anti-MDA5 Aba positive. The patients with anti-MDA5 Abs presented with more apparent cutaneous symptoms and aggressive pulmonary manifestations than did those with anti-Jo-1 Abs. The mortality rate in the anti-MDA5 Abs group (1.95/person-year (PY)) was much higher than that in anti-Jo-1 Abs group (0.094/PY), and most of the mortalities occurred within the first 1–3 months of follow-up. Conclusion. Distinct cutaneous and pulmonary manifestations were observed in the anti-Jo-1 Abs and anti-MDA5 Abs groups. The mortality rate in the anti-MDA5 Abs group was significantly higher than that in the anti-Jo-1 Abs group. Early recognition is crucial to ensuring higher chances of survival for patients with anti-MDA5 Abs. |
| format | Article |
| id | doaj-art-dd1fefa3348449d0aaf0d1bd030a2231 |
| institution | Kabale University |
| issn | 2314-7156 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-dd1fefa3348449d0aaf0d1bd030a22312025-08-20T03:25:14ZengWileyJournal of Immunology Research2314-71562023-01-01202310.1155/2023/2988422Differences in the Clinical Characteristics and 1-Year Mortality Rates of Patients with Dermatomyositis with anti-Jo-1 and anti-MDA5 AntibodiesChao-Han Liu0Chew-Teng Kor1Ming-Hui Hung2Kai-Hung Hsiao3Yen-Huang Cheng4Ya-Chih Tien5Division of AllergyBig Data CenterDivision of AllergyDivision of AllergyDepartment of Emergency MedicineDivision of AllergyObjective. Patients with anti-Jo-1 antibodies (Abs) and anti–melanoma differentiation-associated protein 5 (MDA5) Abs are at a higher risk of interstitial lung disease (ILD) and have a mortality rate higher than that of patients with anti-Jo-1 Abs. This study investigated differences in the clinical characteristics and prognosis of patients with anti-Jo-1 Abs and anti-MDA5 Abs with dermatomyositis (DM). Methods. We retrospectively reviewed the medical records of 38 patients with DM from January 2000 to December 2021. The patients were divided into anti-Jo-1 Abs and anti-MDA5 Abs groups. The basic demographic data, clinical manifestations, and 1-year mortality rates of the groups were compared. Results. Among the 38 patients, 30 were anti-Jo-1-Abs positive and 8 patients were anti-MDA5 Aba positive. The patients with anti-MDA5 Abs presented with more apparent cutaneous symptoms and aggressive pulmonary manifestations than did those with anti-Jo-1 Abs. The mortality rate in the anti-MDA5 Abs group (1.95/person-year (PY)) was much higher than that in anti-Jo-1 Abs group (0.094/PY), and most of the mortalities occurred within the first 1–3 months of follow-up. Conclusion. Distinct cutaneous and pulmonary manifestations were observed in the anti-Jo-1 Abs and anti-MDA5 Abs groups. The mortality rate in the anti-MDA5 Abs group was significantly higher than that in the anti-Jo-1 Abs group. Early recognition is crucial to ensuring higher chances of survival for patients with anti-MDA5 Abs.http://dx.doi.org/10.1155/2023/2988422 |
| spellingShingle | Chao-Han Liu Chew-Teng Kor Ming-Hui Hung Kai-Hung Hsiao Yen-Huang Cheng Ya-Chih Tien Differences in the Clinical Characteristics and 1-Year Mortality Rates of Patients with Dermatomyositis with anti-Jo-1 and anti-MDA5 Antibodies Journal of Immunology Research |
| title | Differences in the Clinical Characteristics and 1-Year Mortality Rates of Patients with Dermatomyositis with anti-Jo-1 and anti-MDA5 Antibodies |
| title_full | Differences in the Clinical Characteristics and 1-Year Mortality Rates of Patients with Dermatomyositis with anti-Jo-1 and anti-MDA5 Antibodies |
| title_fullStr | Differences in the Clinical Characteristics and 1-Year Mortality Rates of Patients with Dermatomyositis with anti-Jo-1 and anti-MDA5 Antibodies |
| title_full_unstemmed | Differences in the Clinical Characteristics and 1-Year Mortality Rates of Patients with Dermatomyositis with anti-Jo-1 and anti-MDA5 Antibodies |
| title_short | Differences in the Clinical Characteristics and 1-Year Mortality Rates of Patients with Dermatomyositis with anti-Jo-1 and anti-MDA5 Antibodies |
| title_sort | differences in the clinical characteristics and 1 year mortality rates of patients with dermatomyositis with anti jo 1 and anti mda5 antibodies |
| url | http://dx.doi.org/10.1155/2023/2988422 |
| work_keys_str_mv | AT chaohanliu differencesintheclinicalcharacteristicsand1yearmortalityratesofpatientswithdermatomyositiswithantijo1andantimda5antibodies AT chewtengkor differencesintheclinicalcharacteristicsand1yearmortalityratesofpatientswithdermatomyositiswithantijo1andantimda5antibodies AT minghuihung differencesintheclinicalcharacteristicsand1yearmortalityratesofpatientswithdermatomyositiswithantijo1andantimda5antibodies AT kaihunghsiao differencesintheclinicalcharacteristicsand1yearmortalityratesofpatientswithdermatomyositiswithantijo1andantimda5antibodies AT yenhuangcheng differencesintheclinicalcharacteristicsand1yearmortalityratesofpatientswithdermatomyositiswithantijo1andantimda5antibodies AT yachihtien differencesintheclinicalcharacteristicsand1yearmortalityratesofpatientswithdermatomyositiswithantijo1andantimda5antibodies |